Key Account Specialist
About the job
- A bachelor's degree in biological sciences, pharmacy, business-related field, or equivalent.
- Relevant experience with a demonstrated track record of success in a sales or consultative selling role within the biotechnology or pharmaceutical industry.
- Ability to translate strategies into actionable and realistic key account engagement plans.
- Ability to lead, motivate, and coordinate cross-functional teams in the field.
- Ability to negotiate, close, and sign contracting and tendering deals with key accounts and complex customer networks.
- Solid analytical, business planning, and financial acumen skills, with solid working knowledge of pharmacoeconomic principles.
- Solid knowledge of payer and provider mindsets and motivations in the relevant local context.
- Solid knowledge of payer and provider decision-making processes, including key stakeholders and influencers.
- English language proficiency verbally and in writing for non-English-speaking countries.
- Achieve a deep understanding of the complexities, pressures, and opportunities associated with the decision-making matrix within each account, and articulate predicted payer, provider, and influencer decision drivers and unmet needs to brand teams.
- Highlight the cross-functional impacts of anticipated changes in the payer and provider environment to in-field teams and brand teams.
- Build trusted and strategic relationships with payers and providers to anticipate access barriers and better meet the agendas, plans, and objectives of each key account.
- Identify opportunities and collaborate cross-functionally on win-win partnerships with key accounts to positively influence contracting and tendering opportunities for product access.
- Develop account-specific strategies and concise engagement plans with clear objectives and activities to optimize usage, funding, and access of products while considering long-term portfolio goals.
- Negotiate, close, and sign deals, and support or lead the contracting and tendering process, including facilitating the development and delivery of proposals to meet profit targets.
- Regularly track the execution and impact of activities and key-account performance to continuously improve bottom-line impact.
- Demonstrated track record of success with specific key accounts, including strategic long-term and tactical payer or provider experience within the relevant local context.
- Leadership experience within specific key accounts through participation in key-account decision-making processes in contracting and tendering situations, if relevant.
About the company
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
- EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
- JUVMO launches in October 2026, adding a fresh neuroscience revenue line.
What critics are saying
- Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
- Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
- Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.
What makes AbbVie unique
- Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
- JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
- AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Remote Work Options
- Flexible Work Hours
- Professional Development Budget